80 related articles for article (PubMed ID: 3704125)
1. [Detection of bone metastases using hydroxyproline excretion].
Knorr A; Engelmann U; Gross C; Friedrich S
Radiobiol Radiother (Berl); 1986; 27(1):31-4. PubMed ID: 3704125
[No Abstract] [Full Text] [Related]
2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
3. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
[No Abstract] [Full Text] [Related]
4. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
5. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Ditzel J; Jordal R; Riskoer N
Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
[No Abstract] [Full Text] [Related]
6. [Value of the determination of urinary hydroxyproline in the detection of bone metastases].
Sanz Ortiz J; Mayo Suárez J; Riancho Moral JA; Amado Señarís JA
Med Clin (Barc); 1983 Sep; 81(7):296-8. PubMed ID: 6645671
[No Abstract] [Full Text] [Related]
7. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
8. [Hydroxyproline excretion in the urine in destructive bone processes].
Raab W; Schwägerl W
Wien Klin Wochenschr; 1967 Jan; 79(2):32-5. PubMed ID: 6031951
[No Abstract] [Full Text] [Related]
9. Urinary hydroxyproline excretion in orthopedic disease, with special reference to systemic bone disease and bone tumor (secondary report).
Nakagawa M; Sugiura Y; Oshima T; Kajino G; Hirako H
Nagoya J Med Sci; 1967 Mar; 29(4):345-67. PubMed ID: 6066099
[No Abstract] [Full Text] [Related]
10. [Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
Mühlbach R
Beitr Orthop Traumatol; 1966 Oct; 13(10):606-8. PubMed ID: 5977397
[No Abstract] [Full Text] [Related]
11. [Total urinary hydroxyproline excretion in bone tumors].
Oshima T
Nihon Seikeigeka Gakkai Zasshi; 1967 Dec; 41(9):977-90. PubMed ID: 5245306
[No Abstract] [Full Text] [Related]
12. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
[No Abstract] [Full Text] [Related]
13. Study of hydroxyproline excretion in patients with prostatic cancer.
Romics I; Budavári I; Kisbenedek L; Balogh F
Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyproline and zinc excretion in patients with neoplastic breast disease.
Percudani M; Dell'Anna B; De Lorenzis GF; Ferraccioli GF; Vaona GL
Int Surg; 1981; 66(3):233-6. PubMed ID: 7319736
[TBL] [Abstract][Full Text] [Related]
15. Urinary hydroxyproline excretion in patients with breast cancer.
Cuschieri A; Felgate R
Br J Surg; 1971 Nov; 58(11):862. PubMed ID: 5124876
[No Abstract] [Full Text] [Related]
16. Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Niell HB; Palmieri GM; Neely CL; Maxwell TA; Hopkins SC; Soloway MS
Arch Intern Med; 1983 Oct; 143(10):1925-7. PubMed ID: 6625779
[TBL] [Abstract][Full Text] [Related]
17. [Hydroxyproline in generalized bone diseases].
Czitober H; Raab W
Dtsch Med J; 1970 Jun; 21(12):857-64. PubMed ID: 5512354
[No Abstract] [Full Text] [Related]
18. Hydroxyproline excretion in malignant neoplastic disease.
Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
[No Abstract] [Full Text] [Related]
19. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
[TBL] [Abstract][Full Text] [Related]
20. [Urinary hydroxyproline excretion in generalized bone diseases].
Czitober H; Raab W
Wien Z Inn Med; 1967; 48(10):401-8. PubMed ID: 5620579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
